Congress Urged Not to Slash Cancer Research Funding in 'Fiscal Cliff' Negotiations

Share this article:
(ChemotherapyAdvisor) – The Lung Cancer Alliance (LCA), a patient-advocacy organization, is urging Congress to “hold cancer research harmless from the fiscal cliff” during upcoming budget negotiations.

With Congress and the White House looking for ways to curtail the growth of federal spending, it is important to view cancer research budgets as “not a luxury but a necessity,” said LCA President and CEO Laurie Fenton-Ambrose.

"The incidence rate of cancer is higher now than it was 40 years ago and it is the leading cause of death in adults under the age of 75," Fenton-Ambrose said. "With the number of patients and the cost of treatment escalating, we cannot afford to short-change the agencies of government involved in cancer research and the review of new and more targeted cancer drugs now."

More funding needs to be devoted to cancers associated with high mortality rates, she argued – including lung and pancreatic cancers, which represent an estimated 33% of cancer deaths in the United States but research for which is less well-funded than other types of cancer.

She also called for a comprehensive action plan to guide public funding decisions for cancer research, and a system of benchmarks with which research outcomes can be assessed.

"This is the taxpayers' money we are investing in cancer research and treatment development and there has to be more accountability," she said.

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Lung Cancer

PORT Can Improve Survival for Non-Small Cell Lung Cancer (NSCLC) Patients

PORT Can Improve Survival for Non-Small Cell Lung ...

Patients who underwent post-operative radiation therapy (PORT) for non-small cell lung cancer (NSCLC) survived 4 months longer.

Keytruda Designated Breakthrough Status by FDA for Treatment of Non-Small Cell Lung Cancer (NSCLC)

Keytruda Designated Breakthrough Status by FDA for Treatment ...

FDA has designated Keytruda (pembrolizumab) as breakthrough therapy for ALK-negative non-small cell lung cancer (NSCLC).

Early Palliative Care Does Not Increase Costs in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

Early Palliative Care Does Not Increase Costs in ...

Palliative Care in Oncology Symposium: Palliative care for non-small cell lung cancer may not increase healthcare costs in the last 30 days of life.